Display options
Cite
Skeith L, Le Gal G, Rodger MA. Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?. Thromb Res. 2021;202:134-138doi: 10.1016/j.thromres.2021.03.012.
Skeith, L., Le Gal, G., & Rodger, M. A. (2021). Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?. Thrombosis research, 202134-138. https://doi.org/10.1016/j.thromres.2021.03.012
Skeith, Leslie, et al. "Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?." Thrombosis research vol. 202 (2021): 134-138. doi: https://doi.org/10.1016/j.thromres.2021.03.012
Skeith L, Le Gal G, Rodger MA. Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?. Thromb Res. 2021 Jun;202:134-138. doi: 10.1016/j.thromres.2021.03.012. Epub 2021 Mar 25. PMID: 33836493.
Copy Download .nbib Format: NLM
Share it on

Thromb Res. 2021 Jun;202:134-138. doi: 10.1016/j.thromres.2021.03.012. Epub 2021 Mar 25.

Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?.

Thrombosis research

Leslie Skeith, Grégoire Le Gal, Marc A Rodger

Affiliations

  1. Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Alberta, Canada. Electronic address: [email protected].
  2. Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  3. Department of Medicine, McGill University, Montreal, Quebec, Canada.

PMID: 33836493 DOI: 10.1016/j.thromres.2021.03.012

Abstract

Exogenous hormone therapies, such as combined oral contraceptives (COC) and hormone replacement therapy (HRT), cause blood hypercoagulability and are a risk factor for venous thromboembolism (VTE). There is controversy on how strong this "provoking" risk factor is, and how other risk factors may synergise VTE risk. We aim to review the latest literature on the risk of initial and recurrent VTE with COC and HRT use to provide guidance for decision-making about duration of anticoagulation, and guide future research efforts.

Copyright © 2021 Elsevier Ltd. All rights reserved.

Keywords: Contraceptives, oral; Estrogen replacement therapy; Venous thromboembolism

Substances

MeSH terms

Publication Types